Home › Groups › Coalition of Rheumatology Educators ›

Rheumatology: Virtual Case-Based Patient Visits

Course Format: 
On-Demand Webcast
Conference date: 
Tue, 2010-07-20 - Mon, 2011-09-19
$0.00
SKU: 2010-374-2

 

 


 

FACULTY

Philip Mease, MD
Director, Rheumatology Research
Swedish Medical Center
Clinical Professor
University of Washington
Seattle, WashingtonJonathan Kay, MD
Professor of Medicine
University of Massachusetts Medical School
Worcester, Massachusetts
To be eligible for credit, participants must complete the educational activity, complete the 5-question online post-test with a score of 80% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

Release Date: July 20, 2010
Expiration Date: July 19, 2011

Estimated time to complete: 0.75 hours

For questions regarding this educational activity, please contact info@naccme.com.

Hardware/Software Requirements
PC
Internet Explorer (v6 or greater), or Firefox
MAC
Safari
Please direct technical questions to webmaster@naccme.com.
 
 
CME Accreditation
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
The University of Cincinnati designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.
 
Independent Clinical Reviewer: Mandana Hashefi, MD, FACR, Medical Faculty Associates, Division of Rheumatology, George Washington University, Washington, DC
 
Planning Committee
The planning committee comprises Jonathan Kay, MD, Philip J. Mease, MD, and Mandana Hashefi, MD; Kay Weigand, University of Cincinnati; Randy Robbin, Emilie McCardell, John Savage, and William Kormos, NACCME.
 
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
 
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
 
The faculty has reported the following:
 
Dr. Kay: Grant/Research Support—Centocor Ortho Biotech Inc, F. Hoffman La Roche Ltd, Novartis Pharmaceuticals, sanofi-aventis; Consultant—Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Inc, F. Hoffman La Roche Ltd, Genentech Inc, Human Genome Sciences, sanofi-aventis, UCB Inc; Scientific Advisor—Array BioPharma
 
Dr. Mease: Grant/Research Support—Abbott Laboratories, Amgen Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, F. Hoffman La Roche Ltd, Genentech Inc, Pfizer Inc, UCB Inc, Wyeth Pharmaceuticals; Consultant—Abbott Laboratories, Amgen Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, F. Hoffman La Roche Ltd, Genentech Inc, Pfizer Inc, UCB Inc, Wyeth Pharmaceuticals; Promotional Speakers' Bureau—Abbott Laboratories, Amgen Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, Genentech Inc, Pfizer Inc, UCB Inc, Wyeth Pharmaceuticals
 
Dr. Hashefi: Has disclosed no relevant financial relationships with any commercial interests.
 
Planning Committee members Ms. Weigand, Mr. Robbin, Ms. McCardell, Mr. Savage, and Mr. Kormos have reported no relevant financial relationships with any commercial interests.
 
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentation.
 
Faculty have disclosed that the use of diclofenac, methotrexate, naproxen sodium, sulfasalazine, and NSAIDs for the treatment of spondyloarthropathy will be discussed.

Privacy Policy
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate reporting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
 
Copyright © 2010 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
 
Grant Support
Supported by educational grants from Genentech, Inc and Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, UCB Inc, and Abbott Laboratories.
 
Supported by an educational donation provided by Amgen and Wyeth Pharmaceuticals.

 

Program Information
Therapeutic areas: 
Rheumatology
Learning Objectives: 

 

 

Upon completion of the activity, participants should be able to:

  1. Explain how clinical measurement tools have been used to achieve tight spondyloarthopathy (SpA) control and summarize how these tools can be used in clinical practice to optimize patient care
  2. Describe advances in imaging techniques for the diagnosis of SpA and evaluation of disease progression
  3. Outline genetic associations, laboratory markers, and clinical manifestations which should be considered when initiating early, aggressive therapy
  4. Compare and contrast diagnostic practices and treatment approaches for patients with SpA versus rheumatoid arthritis (RA)
Accreditation: 
CME
Price: $0.00
Conference days: 
Title Status
Jessica: 35-Year-Old White Female Tue, 2010-07-20 00:00 - Tue, 2011-09-13 00:00 Closed
Carol 44 Year-Old Female Register now